Advertisement
Organisation › Details
Anifera Ltd.
Anifera aims to be the leader in developing solutions for adjunct therapy with antibiotics; therefore, improving their efficacy and ultimately reducing their use in animals. Anifera’s technology consists of a family of small molecules which, acting through a novel mechanism of action, have been shown to increase the susceptibility of resistant strains of bacteria to antibiotics. With an initial focus on bovine mastitis, significant benefits are expected if the compounds produce a superior bacterial cure. The company was formed by Stonehaven Incubate and Agile Sciences in 2020. *
Start | 2020-01-01 established | |
Industry | animal health | |
Industry 2 | veterinary drug_o | |
Street | 7-12 Tavistock Square | |
City | WC1H 9LT London | |
Address record changed: 2021-09-14 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Anifera Ltd.. (9/14/21). "Press Release: Anifera Awarded Seed Funding for Research from UK’s Centre for Innovation Excellence in Livestock (CIEL)". London. | ||
Record changed: 2021-09-14 |
Advertisement
More documents for Anifera Ltd.
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top